Business Standard

Novartis, Gilead veteran named Glenmark's innovative business CEO

Riva's appointment as CEO of Glenmark's innovation business is effective from April 2.

Glenmark Pharmaceuticals
Premium

Glenmark Pharmaceuticals

Sohini Das Mumbai
Drug major Glenmark Pharmaceuticals, which recently decided to spin off its innovation business into a separate company in the US, has roped in Alessandro Riva, a Gilead and Novartis veteran, as chief executive officer (CEO). 

Riva, who joined Gilead about two years back, is leaving his post as executive vice-president of oncology. 

His appointment as CEO of Glenmark’s innovation business is effective from April 2. 

In mid-February, Glenmark said it has received an in-principle approval from its board to spin off the innovation business into a new company that would be headquartered in the US. The Paramus (New Jersey) company would be a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in